Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug

Haematologica. 2004 Nov;89(11):1284.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Adult
  • Humans
  • Hydroxyurea / adverse effects
  • Hydroxyurea / therapeutic use
  • Middle Aged
  • Pipobroman / adverse effects
  • Pipobroman / therapeutic use*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prognosis
  • Risk Factors
  • Thrombocythemia, Essential / complications
  • Thrombocythemia, Essential / drug therapy*
  • Thromboembolism / etiology
  • Thromboembolism / prevention & control*

Substances

  • Platelet Aggregation Inhibitors
  • Pipobroman
  • Hydroxyurea